Methods for modulating RNA splicing
In one aspect, described herein is a recognition element for splicing modifier (REMS) that can be recognized by a compound provided herein. In another aspect, described herein are methods for modulating the amount of a product of a gene, wherein a precursor RNA transcript transcribed from the gene contains a REMS, and the methods utilizing a compound described herein. More particularly, described herein are methods for modulating the amount of an RNA transcript or protein product encoded by a gene, wherein a precursor RNA transcript transcribed from the gene comprises a REMS, and the methods utilizing a compound described herein. In another aspect, provided herein are artificial gene constructs comprising a REMS, and uses of those artificial gene constructs to modulate functional protein production. In another aspect, provided herein are methods for altering endogenous genes to comprise a REMS, and the use of a compound described herein to modulate the functional protein produced from such altered endogenous genes.
1. A method for regulating the amount of a functional protein produced from an artificial gene construct in a cell obtained from a human subject, the method comprising: (a) contacting the artificial gene construct or a vector comprising the artificial gene construct with the cell; and (b) contacting a compound or a form thereof with the cell, wherein the artificial gene construct comprises: (A) a DNA sequence encoding exons and one, two or more introns, wherein a nucleotide sequence encoding a 5′ splice site, which is upstream of a nucleotide sequence encoding a branch point and a nucleotide sequence encoding a 3′ splice site, contains a nucleotide sequence encoding a non-endogenous recognition element for splicing modifier (REMS), wherein the non-endogenous REMS in the DNA sequence comprises the sequence ANGAgtrngn (SEQ ID NO: 7), wherein r is A or G and N or n is any nucleotide; or (B) an RNA sequence comprising exons and one, two or more introns, wherein a 5′ splice site, which is upstream of a branch point and a 3′ splice site, contains a non-endogenous REMS, wherein the non-endogenous REMS in the RNA sequence comprises the sequence ANGAgurngn (SEQ ID NO: 3), wherein r is A or G and N or n is any nucleotide, and
wherein the compound is:
and
wherein contacting the cell with the artificial gene construct or the vector and the compound or a form thereof occurs in cell culture.
2. The method of claim 1 , wherein the vector is a viral vector.
3. The method of claim 2 , wherein the viral vector is an adeno-associated virus, an adenovirus, a retrovirus, a lentivirus, a Newcastle disease virus, a herpes virus, an alphavirus, or a vaccinia virus.
4. The method of claim 1 , wherein the artificial gene construct further comprises a promoter, a poly(A) site, a transcription termination site, and a transcription binding site.
5. The method of claim 1 , wherein the non-endogenous REMS in the DNA sequence comprises the sequence ANGAgtragt (SEQ ID NO: 8), wherein r is A or G and N is any nucleotide.
6. The method of claim 1 , wherein the non-endogenous REMS in the RNA sequence comprises the sequence ANGAguragu (SEQ ID NO: 4), wherein r is A or G and N is any nucleotide.
7. A method for regulating the amount of a functional protein produced from an artificial gene construct in a cell obtained from a human subject, the method comprising contacting a compound or a form thereof with the cell, wherein the cell was previously contacted with the artificial gene construct or a vector comprising the artificial gene construct, wherein the artificial gene construct comprises: (A) a DNA sequence encoding exons and one, two or more introns, wherein a nucleotide sequence encoding a 5′ splice site, which is upstream of a nucleotide sequence encoding a branch point and a nucleotide sequence encoding a 3′ splice site, contains a nucleotide sequence encoding a non-endogenous recognition element for splicing modifier (REMS), wherein the non-endogenous REMS in the DNA sequence comprises the sequence ANGAgtrngn (SEQ ID NO: 7), wherein r is A or G and N or n is any nucleotide; or (B) an RNA sequence comprising exons and one, two or more introns, wherein a 5′ splice site, which is upstream of a branch point and a 3′ splice site, contains a non-endogenous REMS, wherein the non-endogenous REMS in the RNA sequence comprises the sequence ANGAgurngn (SEQ ID NO: 3), wherein r is A or G and N or n is any nucleotide, and
wherein the compound is:
and
wherein contacting the compound or a form thereof with the cell occurs in cell culture.
8. The method of claim 7 , wherein the vector is a viral vector.
9. The method of claim 8 , wherein the viral vector is an adeno-associated virus, an adenovirus, a retrovirus, a lentivirus, a Newcastle disease virus, a herpes virus, an alphavirus, or a vaccinia virus.
10. The method of claim 7 , wherein the artificial gene construct further comprises a promoter, a poly(A) site, a transcription termination site, and a transcription binding site.
11. The method of claim 7 , wherein the non-endogenous REMS in the DNA sequence comprises the sequence ANGAgtragt (SEQ ID NO: 8), wherein r is A or G and N is any nucleotide.
12. The method of claim 7 , wherein the non-endogenous REMS in the RNA sequence comprises the sequence ANGAguragu (SEQ ID NO: 4), wherein r is A or G and N is any nucleotide.
13. The method of claim 1 , wherein the functional protein is a therapeutic protein.
14. The method of claim 7 , wherein the functional protein is a therapeutic protein.